OBJECTIVES: To investigate the relationship between volume-based PET parameters and prognosis in patients with soft tissue sarcoma (STS). METHODS: We retrospectively reviewed 55 patients with pathologically proven STS who underwent pretreatment with (18) F-Fluorodeoxyglucose ((18)F-FDG) PET/CT. The maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors were measured using a threshold SUV as liver activity for determining the boundary of tumors. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables. RESULTS: Cancer-related death occurred in 19 of 55 patients (35 %) during the follow-up period (29 ± 23 months). On univariate analysis, AJCC stage (stage IV vs. I-III, hazard ratio (HR) = 2.837, p = 0.028), necrosis (G2 vs. G0-G1, HR = 3.890, p = 0.004), SUVmax (1 unit - increase, HR = 1.146, p = 0.008), SUVavg (1 unit - increase, HR = 1.469, p = 0.032) and treatment modality (non-surgical therapy vs. surgery, HR = 4.467, p = 0.002) were significant predictors for overall survival. On multivariate analyses, SUVmax (HR = 1.274, p = 0.015), treatment modality (HR = 3.353, p = 0.019) and necrosis (HR = 5.985, p = 0.006) were identified as significant independent prognostic factors associated with decreased overall survival. CONCLUSIONS: The SUVmax of the primary tumor is a significant independent metabolic prognostic factor for overall survival in patients with STS. Volume-based PET parameters may not add prognostic information outside of the SUVmax.
OBJECTIVES: To investigate the relationship between volume-based PET parameters and prognosis in patients with soft tissue sarcoma (STS). METHODS: We retrospectively reviewed 55 patients with pathologically proven STS who underwent pretreatment with (18) F-Fluorodeoxyglucose ((18)F-FDG) PET/CT. The maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors were measured using a threshold SUV as liver activity for determining the boundary of tumors. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables. RESULTS: Cancer-related death occurred in 19 of 55 patients (35 %) during the follow-up period (29 ± 23 months). On univariate analysis, AJCC stage (stage IV vs. I-III, hazard ratio (HR) = 2.837, p = 0.028), necrosis (G2 vs. G0-G1, HR = 3.890, p = 0.004), SUVmax (1 unit - increase, HR = 1.146, p = 0.008), SUVavg (1 unit - increase, HR = 1.469, p = 0.032) and treatment modality (non-surgical therapy vs. surgery, HR = 4.467, p = 0.002) were significant predictors for overall survival. On multivariate analyses, SUVmax (HR = 1.274, p = 0.015), treatment modality (HR = 3.353, p = 0.019) and necrosis (HR = 5.985, p = 0.006) were identified as significant independent prognostic factors associated with decreased overall survival. CONCLUSIONS: The SUVmax of the primary tumor is a significant independent metabolic prognostic factor for overall survival in patients with STS. Volume-based PET parameters may not add prognostic information outside of the SUVmax.
Authors: J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Tobias Leibold; Timothy J Akhurst; David B Chessin; Henry W Yeung; Homer Macapinlac; Jinru Shia; Bruce D Minsky; Leonard B Saltz; Elyn Riedel; Madhu Mazumdar; Philip B Paty; Martin R Weiser; W Douglas Wong; Steven M Larson; José G Guillem Journal: Ann Surg Oncol Date: 2011-04-08 Impact factor: 5.344
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: Kyoung Jin Chang; Ilhan Lim; Joon Yeun Park; A Ra Jo; Chang Bae Kong; Won Seok Song; Wan Hyeong Jo; Soo Yong Lee; Jae Soo Koh; Byung Il Kim; Chang Woon Choi; Sang Moo Lim Journal: Nucl Med Mol Imaging Date: 2014-10-30
Authors: Elba C Etchebehere; Brian P Hobbs; Denái R Milton; Osama Malawi; Shreyaskumar Patel; Robert S Benjamin; Homer A Macapinlac Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-03 Impact factor: 9.236
Authors: Kim Francis Andersen; Hanna Maria Fuglo; Sine Hvid Rasmussen; Michael Mork Petersen; Annika Loft Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889
Authors: Kim Francis Andersen; Hanna Maria Fuglo; Sine Hvid Rasmussen; Michael Mork Petersen; Annika Loft Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817